EMA approves Imvanex vaccine against monkeypox in EU

Simon Collins, HIV i-Base

On 22 July 2022, the EU committee responsible for reviewing medicines (CHMP) recommended extending the indication for Imvanex to include monkeypox (MPX). [1]

Imvanex was approved in the EU as a smallpox vaccine in 2013. [2]

Imvanex was approved in the US both for smallpox and monkeypox in 2019 where it is marketed as JYYNEOS. [3]

This included additional information from some studies. [4]


  1. EMA News. EMA recommends approval of Imvanex for the prevention of monkeypox disease. (22 July 2022).
  2. EMA. Imvanex product information. (2013).
  3. US FDA, FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox. (24 September 2019)
  4. US Office of Vaccines Research and Review (OVRR). Review memorandum for Jynneos vaccine. (2018)

 This report was first published on 27 July 2022.

Links to other websites are current at date of posting but not maintained.